Atrophin 1 is a protein encoded by the ATN1 gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [1]
ATN1 (Atrophin 1) is a transcriptional co-repressor protein encoded by the ATN1 gene that is highly expressed in the brain. The protein plays critical roles in neuronal development, gene regulation, and cellular survival 1. Pathogenic expansions of a polyglutamine (polyQ) tract in ATN1 cause Dentatorubral-Pallidoluysian Atrophy (DRPLA), a progressive neurodegenerative disorder characterized by cerebellar ataxia, myoclonus, choreoathetosis, and dementia 2. Understanding ATN1's normal functions provides insights into the molecular mechanisms of neurodegeneration and potential therapeutic approaches. [2]
| Feature | Details | [3]
|---------|---------| [4]
| Protein Name | Atrophin 1 | [5]
| Gene Symbol | ATN1 | [6]
| NCBI Protein ID | NP_001021.2 | [7]
| UniProt ID | O15239 | [8]
| Amino Acid Length | 1,185 amino acids | [9]
| Molecular Weight | ~130 kDa |
| Expression | Highest in brain (cerebellum, cerebral cortex, hippocampus), moderate in other tissues |
The ATN1 protein is characterized by an N-terminal acidic domain, a polyglutamine (polyQ) tract that is expanded in disease, a proline-rich region, and a C-terminal basic region that mediates DNA binding and transcriptional repression 3.
ATN1 functions as a transcriptional co-repressor through multiple mechanisms 4:
Direct DNA binding: The C-terminal region of ATN1 can bind to specific DNA sequences, particularly AT-rich regions, to repress transcription.
Protein-protein interactions: ATN1 interacts with multiple transcription factors and co-repressors:
ATN1 exhibits both nuclear and cytoplasmic localization 5:
ATN1 plays essential roles in brain development 6:
ATN1 regulates expression of numerous neuronal genes 7:
Under normal conditions, ATN1 provides neuroprotection through 8:
DRPLA is caused by CAG trinucleotide repeat expansions in the ATN1 gene 2:
| Feature | Normal | Pathogenic |
|---|---|---|
| CAG repeat count | 7-35 | 48-93 |
| Inheritance | Autosomal dominant | Autosomal dominant |
| Penetrance | Complete | Complete |
| Anticipation | No | Yes (maternal bias) |
The polyQ expansion causes toxic gain-of-function, leading to progressive neuronal degeneration 9.
The mutant ATN1 protein causes neurodegeneration through multiple mechanisms 10:
1. Transcriptional dysregulation:
2. Protein aggregation:
3. Loss of normal function:
4. Toxic gain-of-function:
DRPLA neuropathology shows characteristic features 11:
DRPLA presents with progressive neurological symptoms 13:
| Symptom | Frequency | Onset |
|---|---|---|
| Ataxia | 100% | 2nd-4th decade |
| Myoclonus | 70-90% | Variable |
| Dementia | 50-80% | Variable |
| Chorea/athetosis | 50-70% | Variable |
| Seizures | 30-50% | Often childhood |
| Psychiatric symptoms | 30-50% | Variable |
DRPLA diagnosis involves multiple approaches 15:
No disease-modifying treatments exist for DRPLA; management is symptomatic 16:
Several strategies are being explored 17:
1. Gene silencing:
2. Protein targeting:
3. Symptomatic relief:
Ito K, et al. DRPLA neuropathology (1992). 1992. ↩︎
Murone I, et al. Dentatorubral degeneration in DRPLA (1999). 1999. ↩︎
Shiwaku H, et al. DRPLA clinical manifestations (2010). 2010. ↩︎
Kanazawa I, et al. DRPLA disease progression (1999). 1999. ↩︎
Ito D, et al. DRPLA diagnosis (2012). 2012. ↩︎
Tsuzuki K, et al. DRPLA treatment (2001). 2001. ↩︎
Takahashi N, et al. ASO therapy for polyglutamine diseases (2010). 2010. ↩︎
Martindale D, et al. Genetic modifiers of polyglutamine disease (2006). 2006. ↩︎
Okamura-Oho Y, et al. ATN1 protein interactions (2003). 2003. ↩︎